Hepatitis C virus (HCV) infection is a substantial health problem worldwide. Most patients
infected with HCV remain chronically infected, with an increased risk of cirrhosis and …

Liver fibrosis results from an excessive wound healing response in most chronic liver
diseases, such as hepatitis C. Despite great advances in antiviral therapy in recent years …

Background & Aims Interferon alfa–based regimens used to treat recurrent hepatitis C virus
(HCV) infection after liver transplantation are poorly tolerated, associated with generally …

Treatment with an all‐oral interferon‐free antiviral regimen using simeprevir and sofosbuvir
with or without ribavirin (RBV) for 12 weeks resulted in high sustained virologic response …

Background & Aims Protease inhibitors (PI) with peginterferon/ribavirin have significantly
improved SVR rates in HCV G1 patients. Their use to treat HCV recurrence after liver …

Pegylated interferon (pegIFN) and ribavirin eradicates hepatitis C virus (HCV) in one third of
liver recipients with recurrent disease. Side effects are frequent and potentially life …

Background and Aims Hepatitis C virus (HCV)‐viremic organs are underutilized, and there is
limited real‐world experience on the transplantation of HCV‐viremic solid organs into …

Background & Aims Sofosbuvir, an NS5B inhibitor, combined with velpatasvir, an NS5A
inhibitor (SOF/VEL), produces high sustained virologic response rates 12 weeks after …

The safety, efficacy, and effect on immunosuppression levels of telaprevir (TVR) or
boceprevir (BOC) in combination with peginterferon (PEG‐IFN) and ribavirin (RBV) in …

A number of hepatotrophic viruses affect organ transplant candidates and recipients. The
most important agents causing acute and chronic hepatitis are hepatitis B virus (HBV), with …